about
USL255 extended-release topiramate for the treatment of epilepsy.An update and review of the treatment of myoclonus.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Third generation antiepileptic drug monotherapies in adults with epilepsy.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.Drug development: Illuminated targets.
P2860
Q38249142-9260C15E-CF56-4955-9380-B9AF28071731Q38268299-935A9A1C-9A00-4D63-BD46-A1C40DDCAD4CQ38614499-913820A1-FF37-414F-8427-6273514B03C0Q38849966-535FD90A-4B47-4BD4-B384-8DEBCFC89D43Q38985697-F616BAB4-AC53-4C4D-94B1-2F4E81AF72C6Q40215881-F5DAF268-F874-40D3-8A0C-F866246361D1Q48070946-F3CE57EB-A265-4D45-A378-CD4F6411DB9B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Brivaracetam for the treatment of epilepsy in adults.
@en
type
label
Brivaracetam for the treatment of epilepsy in adults.
@en
prefLabel
Brivaracetam for the treatment of epilepsy in adults.
@en
P2860
P1476
Brivaracetam for the treatment of epilepsy in adults
@en
P2093
Marco Mula
P2860
P304
P356
10.1586/14737175.2014.896200
P50
P577
2014-04-01T00:00:00Z